Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Triple Negative Breast Cancer, Hormone-R...
Phase PHASE1
Enrollment 77
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD) and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before the dose expansion portion (1B) of the study is initiated. The dose escalation portion of this study (1A) will also be used to determine the recommended phase 2 dose (RP2D) of AG01 antibody to be evaluated in the cohort expansion portion (1B).

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: AG-01 Compound — Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses. Phase 1B patients will be treated with AG-01 at the RP2D.

Primary Outcomes

  • Maximum Tolerated Dose (MTD) and/or Maximum Administered Dose (MAD) (28 days during 1st cycle)
  • Antitumor Activity of AG-01 by Overall Response Rate (ORR) (Every 56 Days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-02-14
Completion: 2026-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 77 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: A&G Pharmaceutical Inc.
Collaborators: University of Maryland Greenebaum Cancer Center
Principal Investigators:
  • Katherine Tkaczuk, MD (PRINCIPAL_INVESTIGATOR) - University of Maryland, Baltimore
Contact Information
Study Contact:
Ginette Serrero, PhD/DSC.
(410)884-4100
gserrero@agpharma.com
Katherine Tkaczuk, MD
(410) 328-7394
ktkaczuk@umm.edu
Katherine Tkaczuk, MD
410-328-7394
ktkaczuk@umm.edu
University of Maryland Greenebaum Comprehensive Cancer Center
Interventions
  • Drug: AG-01 Compound — Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses. Phase 1B patients will be treated with AG-01 at the RP2D.
Study Locations (1 sites)
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland 21201 United States
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent/authorization is obtained prior to conducting any study-specific screening procedures. 2. 18 years of age or older. 3. Histologic or cytologic diagnosis of advanced cancer. 4. Radiographic evidence of at least 1 measurable metastatic lesion per RECIST 1.1 criteria. 5. Patients with relapsed/refractory solid tumor malignancies who failed one or more standard chemotherapy or targeted therapy regimens per SOC guidelines such as NCCN guidelines and for whom no standard therapy exists (Phase 1A). No GP88 expression pre-required for phase 1A. 6. For phase 1B, patients must have GP88 tissue tumor tissue expression of 1+, 2+ or 3+ by IHC, archival tumor tissue will be used whenever possible. If no archival tissue is available, subject will be asked to consent to a study specific tumor biopsy for GP88 testing (phase1B). Patients who do not have archival tissue available for the dose expansion cohort (1B) will not be exposed to significant risk procedure to obtain tissue and may still be eligible for the study, after discussion with the Sponsor and Medical Monitor. 7. At least 4 weeks after the last dose of chemotherapy or radiation therapy; 6 weeks for mitoxantrone or mitomycin therapy. 8. ECOG performance status must be ≤2 (Appendix A). 9. Adequate hepatic, renal, and bone marrow function: Absolute neutrophil count ≥ 1,000/uL Platelets ≥ 100,000/µL Total bilirubin WNL per Institution ULN AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional ULN Creatinine ≤1.2 mg/dL Clearance ≥50ml/min (Cockcroft-Gault) 10. All study participants (male and female) with reproductive potential must practice highly effective methods of contraception (failure rate \<1% annually) while on this study and for 90 days after completion of study therapy. 11. Men and women of all ethnic groups are eligible for this trial. 12. Females at reproductive age must have a negative urine pregnancy test prior to entry to this study. 13. Males with partners at reproductive age must use highly effective birth control methods to prevent partners' pregnancy while on study and for 90 days after completion of study treatments. 14. Life expectancy is greater than 12 weeks. 15. Subjects with triple negative breast cancer (TNBC) cohort must have received 1 or more standard of care (SOC) or targeted therapies for metastatic TNBC. If PD(L)1-positive, must have received a combination of chemotherapy and a PD (L)-1 agent (Atezolizumab or Pembrolizumab), unless not a candidate for these therapies. If gBRCA 1 or 2 mutation is present, must have received SOC therapies including a PARPi, unless not a candidate for these therapies. is FDA approved for treatment of advanced TNBC. Prior exposure to Sacituzumab Govitecan ADC therapy does not preclude eligibility in the current study. 16. Subjects with Cohort 2-Breast Cancer ER and/or PR positive, hormone-resistant breast cancer who received 1 or more hormonal (HT) therapies or HT/CD4/6 kinase inhibitor or HT/MTOR inhibitor for treatment of metastatic breast cancer are eligible. If the tumor has known PIK3CA mutation, HT/Alpelisib combination should be considered unless not a candidate for this therapy. 17. Subjects with metastatic/recurrent NSCLCA who failed 2 or more SOC therapies, including platinum-based chemotherapy and an anti-PD (L) -1 agent (sequentially or consecutively). Patients with sensitizing mutations/alterations/rearrangements are eligible if received 1 or more SOC agent/s targeting these mutations unless not a candidate for these therapies. 18. Mesothelioma patients who have received at least 1 SOC therapy for metastatic/recurrent mesothelioma per NCCN recommendations or not a candidate for SOC therapy. Exclusion Criteria: 1. Uncontrolled inter-current illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias not well controlled with medication, myocardial infarction within the previous 6 months, or psychiatric illness/social situations that would limit compliance with study requirements. 2. Uncontrolled or untreated CNS metastases and treated CNS metastases are allowed, as long as the patient is clinically stable. 3. Presence carcinomatous meningeal involvement. 4. Patients may not be receiving any other investigational agents, or have participated in any investigational drug study \< 28 days prior to starting on the current study. 5. Since the teratogenic potential of AG01 is currently unknown, females who are pregnant or lactating are excluded. 6. Males and females unable to adhere to abstinence or use highly effective methods of contraception (annual failure rate \< 1%) to prevent study subjects' pregnancy or study subjects' partner pregnancy. 7. History of any other malignancies in the last 2 years except for in-situ cancer, basal or squamous cell skin cancer treated with curative intent.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Chemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of "chemo fog" also known as "chemobrain" has not been fully investigated and is often based on comments of breast cancer patients attending outpatient clinics during and after their chemotherapy. Changes in thinking ability like lack of concentration, loss of memory and the inability to hold a thought or even a conversation has a significant impact on the lives of breast cancer patients. Without understanding what "chemobrain" is, and what causes it, there is little that doctors can do to help at the moment. The team proposing this study believe that chemotherapy causes chemicals associated with inflammation to attack parts of the brain that are important for concentration and making new memories. Unfortunately, it is not possible to measure these chemicals directly in the brain, but we believe that a brain scan sensitive to excess iron, a marker of brain inflammation, can help. This project will measure thinking ability, such as memory and concentration, take a blood sample and do a brain scan before, during and after a patient has chemotherapy. We will then look for changes in iron in the brain areas that are important for concentration and memory and compare those to changes in thinking ability and to levels of inflammation chemicals in the blood. This information will be essential to help plan our next step which is to test ways to reduce the effects of "chemobrain".

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention — Observation only

Primary Outcomes

  • Cognitive performance late post chemotherapy (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-12-15
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aberdeen
Collaborators: NHS Grampian
Contact Information
Study Contact:
Teresa Morris
+44 + 1224438363
t.morris@abdn.ac.uk
Victoria Murdoch, MBChB
NHS Grampian
Gordon D Waiter, PhD
NHS Grampian
Interventions
  • Other: No intervention — Observation only
Study Locations (1 sites)
NHS Grampian, Aberdeen, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Women and men \>18 years * Diagnosed with HER2 negative breast cancer * Receiving EC-Taxane or Taxane only based chemotherapy * Able to communicate in English * Willing and able to give informed consent for participation in the study. Exclusion Criteria: * Any patient whose physical condition will preclude them from lying still for the duration of the brain scan. * pre-excisting mental condition/disability * Contraindication to magnetic resonance scanning such as an implantable cardiac device.

Stress Reduction Through Acupuncture

NCT07132034
Recruiting
Conditions Acupuncture, Breast Cancer, Survivorship
Phase NA
Enrollment 112
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial evaluates whether eight weeks of weekly acupuncture can reduce psychological distress in breast cancer patients who have recently completed primary therapy compared to standard-of-care wait-list control.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Acupuncture — 8 sessions of acupuncture treatment (body and auricular acupuncture) will be given once a week after randomization.
  • Other: Standard supportive care — Supportive care according to local standards will be given which may also include face-to-face psychosocial support or the participation of support groups

Primary Outcomes

  • Distress at 8 weeks of intervention (Post-intervention (after completion of the 8 week acupuncture therapy or SOC))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-07
Completion: 2029-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 112 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Isabell Xiang Ge
Collaborators: Swiss GO Trial Group
Principal Investigators:
  • Viola Heinzelmann-Schwarz, Prof.MD (STUDY_CHAIR) - University Hospital of Basel
Contact Information
Study Contact:
Isabell Xiang Ge, MD
+41 61 265 85885
isabellxiang.ge@usb.ch
Christian Kurzeder, Prof.MD
+41 61 32 87990
christian.kurzeder@usb.ch
Isabell Xiang Ge, MD
+41 61 265 85885
isabellxiang.ge@usb.ch
University Hospital Basel
Interventions
  • Procedure: Acupuncture — 8 sessions of acupuncture treatment (body and auricular acupuncture) will be given once a week after randomization.
  • Other: Standard supportive care — Supportive care according to local standards will be given which may also include face-to-face psychosocial support or the participation of support groups
Study Locations (3 sites)
University Hospital Basel, Basel, 4031 Switzerland
Gesundheitszentrum Fricktal AG Frauenklinik, Rheinfelden, Switzerland
Onkologie- & Hämatologiezentrums, Spital STS AG Thun, Thun, Switzerland
Eligibility Criteria
Inclusion criteria: * Patients with localized breast cancer having completed primary therapy (operation +/- chemotherapy +/- radiotherapy) in the last 6 months - Distress Thermometer ≥ 5 - Age ≥ 18 years - Signed informed consent for participation of the trial * Prior cancer is allowed * Prior treatment - including chemotherapy - for a prior malignant tumor (including breast cancer) is allowed * Concomitant participation in an experimental therapeutic drug trial is allowed * Ongoing or planned Anti-her2/neu, immune checkpoint inhibitor, antihormonal and CDK4/6 inhibitor therapy or other adjuvant treatment scheduled for \> 3 months during study period is allowed * Use of other complementary methods (including mistletoe) is allowed. Exclusion criteria: * Patients with language or cognitive deficits (including impaired consciousness) that are incompatible with the participation in the study * Severe physical or psychiatric comorbidity that prevents a patient from participating in the study * Patients incapable of giving consent * Pregnancy
Conditions Breast Neoplasms, Triple Negative Breast...
Phase PHASE3
Enrollment 2400
Locations 326 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Sacituzumab tirumotecan — IV infusion
  • Biological: Pembrolizumab — IV infusion
  • Drug: Rescue Medication — Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
  • Drug: Carboplatin — IV infusion
  • Drug: Paclitaxel — IV infusion
  • Drug: Doxorubicin — IV infusion
  • Drug: Epirubicin — IV infusion
  • Drug: Cyclophosphamide — IV infusion

Primary Outcomes

  • Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery (Up to approximately 30 weeks)
  • Event-Free Survival (EFS) (Up to approximately 92 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-06-30
Completion: 2034-12-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Merck Sharp & Dohme LLC
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Merck Sharp & Dohme LLC
Contact Information
Study Contact:
Toll Free Number
1-888-577-8839
Trialsites@msd.com
Study Coordinator
480-256-6444
Banner MD Anderson Cancer Center ( Site 0066)
Study Coordinator
480-574-2802
Mayo Clinic Cancer Center ( Site 0034)
Interventions
  • Biological: Sacituzumab tirumotecan — IV infusion
  • Biological: Pembrolizumab — IV infusion
  • Drug: Rescue Medication — Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
  • Drug: Carboplatin — IV infusion
  • Drug: Paclitaxel — IV infusion
Study Locations (326 sites)
Banner MD Anderson Cancer Center ( Site 0066), Gilbert, Arizona 85234 United States
Mayo Clinic Cancer Center ( Site 0034), Phoenix, Arizona 85054 United States
University of Arizona Cancer Center ( Site 0035), Tucson, Arizona 85719 United States
Roy and Patricia Disney Family Cancer Center ( Site 0055), Burbank, California 91505 United States
Community Cancer Institute ( Site 0100), Clovis, California 93611 United States
Providence Medical Foundation ( Site 0080), Fullerton, California 92835 United States
MemorialCare Health System - Long Beach Medical Center ( Site 9556), Long Beach, California 90806 United States
El Camino Hospital Cancer Center ( Site 0096), Mountain View, California 94040 United States
Hoag Memorial Hospital Presbyterian ( Site 0010), Newport Beach, California 92663 United States
Helios Clinical Research ( Site 0061), Whittier, California 90602 United States
Eligibility Criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per AJCC 8th edition criteria as assessed by the physician investigator based on radiological and/or clinical assessment: * cT1c, N1-N2 * cT2, N0-N2 * cT3, N0-N2 * cT4a-d, N0-N2 * The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2- as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. * Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory. * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1). * Demonstrates adequate organ function. Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement * Has received any prior treatment, including radiation, systemic therapy,and/or definitive surgery for currently diagnosed breast cancer * Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment. * Received prior systemic anticancer therapy including investigational agents within 4 weeks before C1D1. * Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137). * Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC). * Received prior treatment with a topoisomerase I inhibitor-containing ADC. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * Known additional malignancy that is progressing or has required active treatment within the past 5 years. * Uncontrolled systemic disease. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids, has current pneumonitis/interstitial lung disease or has suspected interstitial lung disease (ILD) or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening..

NeoRad Breast Cancer Study

NCT04261244
Recruiting
Conditions Breast Cancer
Phase PHASE3
Enrollment 1826
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The NEORAD trial tests whether preoperative radiotherapy results in an improved DFS and less radiation induced late effect compared to postoperative radiotherapy in higher risk breast cancer after NACT.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: preoperative radiotherapy — preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
  • Radiation: postoperative radiotherapy — postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy

Primary Outcomes

  • disease free survival (DFS): (6 to 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-02-01
Completion: 2034-03-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1826 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bielefeld University
Principal Investigators:
  • Christiane M Prof., MD Prof. (STUDY_CHAIR) - Bielefeld University
Contact Information
Study Contact:
Christiane Matuschek, MD Prof.
+495215812901
christiane.matuschek@uni-bielefeld.de
Deborah Wöstenfeld, M. A.
+495215812972
deborah.woestenfeld@uni-bielefeld.de
Alexandra Nienhaus
+4925619923208
gynaekologie.ahaus@kwml.de
St. Marien-Krankenhaus Ahaus
Interventions
  • Radiation: preoperative radiotherapy — preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
  • Radiation: postoperative radiotherapy — postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
Study Locations (16 sites)
St. Marien-Krankenhaus Ahaus, Ahaus, 48683 Germany
Hochtaunus-Kliniken, Bad Homburg, 61352 Germany
Sana Klinikum Lichtenberg, Berlin, 10365 Germany
St. Agnes-Hospital, Bocholt, 46397 Germany
Städtisches Klinikum Dessau, Dessau, 06847 Germany
Universitätsfrauenklinik UK OWL, Klinikum Lippe, Detmold, 32756 Germany
Universitätsklinikum Düsseldorf, Düsseldorf, 40225 Germany
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg, Georgsmarienhütte, 49124 Germany
Sana Klinikum Hameln-Pyrmont, Hamelin, 31785 Germany
Sana Klinikum Offenbach, Offenbach, 63069 Germany
Eligibility Criteria
Inclusion Criteria: * Histologically proven invasive, unilateral breast cancer * Indication for radiotherapy * Indication for neoadjuvant chemotherapy (+/- antibody treatment or other targeted therapies) in accordance with national and international guidelines * Female * Informed consent for the trial signed by the patient * Hormone receptor and HER2 status: no restrictions * All grades G1-G3 * Age ≥ 18 years at the time of informed consent * Performance status ≤ 2 * No pre-existing conditions that prohibit therapy Exclusion Criteria: * Neoadjuvant treatment solely with endocrine therapy * Bilateral breast cancer * Pregnancy or lactation * Prior radiotherapy of the thorax * Connective tissue disease, including rheumatoid arthritis and thromboangiitis obliterans * Pre-existing symptomatic chronic lung disease (fibrosis, pneumoconiosis, adult-onset allergies, such as farmer's lung, severe lung emphysema, COPD °III) * Cardiac comorbidities: symptomatic coronary heart disease, prior heart attack, heart failure NYHA ≥II or AHA ≥C, pacemaker, and/or implanted defibrillator * Malignoma except basalioma or in-situ-carcinomas in complete response * Distant metastasis * Plexopathies of the arm of the treated side * Stiffness of the shoulder of the arm of the side of the breast cancer of any origin (e.g. following a road accident) * Lymph edema ≥°II of the arm at the side of the breast cancer * Other medical conditions that prohibit the neoadjuvant radiotherapy (i.e. Expected non-compliance, etc.) * Male patients * Patients who have previously been assessed for chemotherapy response
Conditions Hormone Receptor Positive HER-2 Negative...
Phase Not Applicable
Enrollment 504
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

PEAK is a prospective, multicenter, non-interventional investigator-initiated trial (IIT) that aims to investigate the influence of the menstrual cycle phase on Ki67 in patients who either receive Tamoxifen, Aromatase inhibitors ± gonadotropin-releasing hormone (GnRH)-Analogues or nothing or no preoperative endocrine treatment as part of the clinical routine. The investigators moreover address the question whether PAM50 assessment in addition to Ki67 dynamics still impacts treatment recommendations.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Influence of the menstrual cycle on initial Ki67 in premenopausal women (duration of therapy and follow-up data (10 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-25
Completion: 2035-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 504 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Tuebingen
Collaborators: University Hospital Ulm, University Hospital Freiburg
Principal Investigators:
  • Dominik Dannehl, Dr. (PRINCIPAL_INVESTIGATOR) - University Hospital Tuebingen
Contact Information
Study Contact:
Dominik Dannehl, Dr.
07071 29 82211
Dominik.Dannehl@med.uni-tuebingen.de
Dominik Dannehl, Dr.
07071 29 82211
Dominik.Dannehl@med.uni-tuebingen.de
Department of Women's Health
Interventions
N/A
Study Locations (1 sites)
Department of Women's Health, Tübingen, 72076 Germany
Eligibility Criteria
Inclusion Criteria: * women ≥ 18 years of age * histologically proven unilateral primary non-metastatic invasive breast cancer * Estrogen receptor (ER)-/ or Progesterone receptor (PR)- positive and HER2-negative * Ki67 from core biopsy is available * no lymph-node involvement by clinical evaluation and ultrasound (cN0) * not amendable to neoadjuvant chemotherapy * surgery or planned surgery at the Department for Women's Health, Tuebingen or Freiburg * planned preoperative endocrine treatment with Tamoxifen, Aromatase inhibitors, Goserelin or nothing for 2 - 4 weeks * written informed consent Exclusion Criteria: * ER-negative and PR-negative * HER2-positive * bilateral breast cancer * preexisting cancer disease within the last 10 years * preexisting invasive ipsi- or contralateral breast cancer (non-invasive ipsi- or contralateral breast cancer is not regarded as an exclusion criteria) * any systemic breast cancer therapy before inclusion into the trial * indication for neoadjuvant chemotherapy * any systemic therapy except Tamoxifen, Aromatase inhibitors, Goserelin before surgery * locally advanced, inoperable or metastatic breast cancer * pregnant or lactating patients * inadequate general condition (not fit for chemotherapy) * hormonal contraception within 6 months before inclusion
Conditions Breast Cancer
Phase NA
Enrollment 50000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

DianaWeb is a community-based participatory research (CBPR) offered to Italian breast cancer patients. The aim of the study is the evaluation of effectiveness of a lifestyle and nutrition intervention to improve the prognosis. DianaWeb study utilizes an interactive website - http://www.dianaweb.org/ - to monitor patient life-style, and to obtain clinical, pathological and anthropometric data (height, body weight, waist circumference and blood pressure). Detailed instructions were provided for measuring at home. The website contains theoretical and practical advice to encourage women to follow healthy lifestyles and nutrition, and the indications emerging from research for women diagnosed with breast cancer. DianaWeb study intends to recruit 50.000 women with breast cancer diagnosis.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Community-based participatory research on diet and lifestyle — The intervention use a web site that contains a section to exchange information on recipes and on strategy to comply with the recommendations, and an agenda to inform on meetings, conferences, kitchen classes, walking groups, organised by the participant themselves. The investigators are developed specific recommendations for women with different characteristics. The investigators intend to improve the specificity of information with short questionnaires on portion size of relevant items using photographs or usual container in the kitchen and develop a health application for smartphone to facilitated a more efficient and timely exchange on information. The participants will receive a free phone number for emergencies, active 2 hours a day for 5 days a week.

Primary Outcomes

  • Increase rate of survival (Baseline, 10 years)
  • Decrease incidence of relapses (Baseline, 10 years)
  • Decrease incidence of metastasis (Baseline, 10 years)
  • Decrease incidence of Metabolic Syndrome parameters (baseline, 1 year, 5 years, 10 years)
  • Decrease blood level on C-reactive protein (chronic inflammation marker) (baseline, 1 year, 5 years, 10 years)
  • Decrease the insulin resistance index (HOMA index) (baseline, 1 year, 5 years, 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2016-06-21
Completion: 2028-12-31
Eligibility
Age: 18 Years – 90 Years
Sex: FEMALE
Volunteers: false
Enrollment: 50000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators: University Of Perugia, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo, Azienda Socio Sanitaria Territoriale di Mantova, Presidio Ospedaliero Unico "Santa Maria della Misericordia", Urbino, Ospedale Città di Castello- Perugia, University of Urbino "Carlo Bo", Fondazione Vita e Salute
Principal Investigators:
  • ANNA VILLARINI, PhD (PRINCIPAL_INVESTIGATOR) - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Contact Information
Study Contact:
ANNA VILLARINI, PhD
+390223903552
anna.villarini@istitutotumori.mi.it
MILENA VILLARINI, Graduate
+390755857419
milena.villarini@unipg.it
MILENA VILLARINI, GRGADUATE
+390755857419
milena.villarini@unipg.it
Fondazione Irccs Istituto Nazionale Dei Tumori
Interventions
  • Other: Community-based participatory research on diet and lifestyle — The intervention use a web site that contains a section to exchange information on recipes and on strategy to comply with the recommendations, and an agenda to inform on meetings, conferences, kitchen classes, walking groups, organised by the participant themselves. The investigators are developed specific recommendations for women with different characteristics. The investigators intend to improve the specificity of information with short questionnaires on portion size of relevant items using photographs or usual container in the kitchen and develop a health application for smartphone to facilitated a more efficient and timely exchange on information. The participants will receive a free phone number for emergencies, active 2 hours a day for 5 days a week.
Study Locations (1 sites)
Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, MI 20133 Italy
Eligibility Criteria
Inclusion Criteria: * Women with breast cancer diagnosis * Women with breast cancer relapses * Women with breast cancer metastases * Women with breast cancer diagnosis even if many years have elapsed since the first diagnosis * Women with breast cancer diagnosis and other tumors diagnosis * Women with breast cancer diagnosis and other pathologists that impair cognitive abilities Exclusion Criteria: * Women with breast cancer diagnosis and clinical diagnosis of Alzheimer's Disease * Women with breast cancer diagnosis and clinical diagnosis of dementia * Women with breast cancer diagnosis unable to use personal computer and smart phone
Conditions Advanced HR - Positive, HER2 - Negative ...
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study adopts a single-center, open-label, non-randomized trial design. It plans to enroll patients with HR- positive, HER2- negative advanced breast cancer who are resistant to (neo)adjuvant endocrine therapy. Dose-escalation and dose-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with palbociclib and fulvestrant in this patient population, and to confirm the recommended phase 2 dose (RP2D)

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sirolimus (albumin - bound) — Sirolimus (albumin - bound): Dose escalation, intravenous infusion
  • Drug: Palbociclib — Palbociclib: the dosage is 125 mg, orally once a day. taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks
  • Drug: Fulvestrant — Fulvestrant: the dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.

Primary Outcomes

  • The occurrence and frequency of adverse events (AE) (At the end of Cycle 9 (each cycle is 28 days))
  • dose - limiting toxicities (DLT) (At the end of Cycle 9 (each cycle is 28 days))
  • The recommended phase 2 dose (At the end of Cycle 9 (each cycle is 28 days))
  • 4. serious adverse events (SAE) (At the end of Cycle 9 (each cycle is 28 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-28
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhimin Shao, PhD,MD
+086 64175590
zhimingshao@yahoo.com
zuo Wenjia
+86 18018678485
Cancer Hospital Affiliated to Fudan University
Interventions
  • Drug: Sirolimus (albumin - bound) — Sirolimus (albumin - bound): Dose escalation, intravenous infusion
  • Drug: Palbociclib — Palbociclib: the dosage is 125 mg, orally once a day. taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks
  • Drug: Fulvestrant — Fulvestrant: the dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.
Study Locations (1 sites)
Cancer Hospital Affiliated to Fudan University, Shanghai, China
Eligibility Criteria
Inclusion Criteria: * 1\. Subjects should be over 18 years old, regardless of gender. Among them, female patients should be post - menopausal status * 2\. Histologically or cytologically confirmed HR - positive, HER2 - negative advanced breast cancer. * 3\. The investigator assesses that the patient is suitable for palbociclib and fulvestrant treatment at the current stage. * 4\. There is at least one measurable lesion that meets the RECIST V1.1 criteria (only applicable to the dose - expansion stage) * 5\. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 - 1. * 6\. For patients in the dose - escalation stage, there are no restrictions on previous treatments. The investigator needs to determine that the patient is suitable for enrollment in the study and receiving the investigational drugs at the current stage. For patients in the dose - expansion stage, the following criteria must be met: * The patient has received (neo)adjuvant endocrine therapy (either as a single agent or in combination). There should be imaging evidence of breast cancer recurrence or progression during or within 12 months after the completion of (neo)adjuvant endocrine therapy (tamoxifen, AI, or oral SERD). * Patients in the recurrent or metastatic stage have not received systemic chemotherapy. (Note 1: A chemotherapy regimen that is terminated due to toxicity during the first cycle or after the completion of treatment, and there is no clinical or imaging evidence of disease progression at the start of subsequent treatment, is not counted as a line of treatment. Note 2: Adjuvant and neoadjuvant chemotherapy are not classified as lines of treatment for ABC. Note 3: Antibody - drug conjugates are classified as chemotherapy) * Patients in the recurrent or metastatic stage have not received CDK4/6 inhibitor treatment. (Note 1: It is allowed that the patient has received CDK4/6i during (neo)adjuvant therapy, and there is a disease - free interval of at least 12 months (i.e., at least 12 months between the last day of CDK4/6i treatment and the date of recurrence). In addition, drug replacement in patients without disease progression does not count as a new line of treatment) Exclusion Criteria: * 1\. The patient was previously diagnosed with HER2 - positive breast cancer through pathological examination. * 2\. Patients who are judged by the investigator as unsuitable for endocrine therapy (e.g., patients with visceral crisis at immediate risk of life - threatening complications in the short term, including those with a large amount of uncontrolled effusion (pleural, pericardial, and abdominal), lymphangitis carcinomatosa of the lung, or patients with liver involvement \> 50%). * 3\. Patients who have previously received treatment with fulvestrant or inhibitors such as PI3K/AKT/mTOR. * 4\. Patients with third - space fluid accumulation (such as pericardial effusion, pleural effusion, and ascites) that requires repeated drainage or other treatments but remains uncontrollable, and are judged by the investigator as unsuitable for enrollment. * 5\. Patients with a history of severe lung diseases, such as interstitial lung disease and/or pneumonia, or pulmonary hypertension, or radiation pneumonia requiring glucocorticoid treatment. * 6\. Patients with chronic gastrointestinal dysfunction mainly manifested as diarrhea, such as Crohn's disease, ulcerative colitis, malabsorption, or diarrhea of grade ≥ 1; intestinal obstruction, or other gastrointestinal diseases judged to be clinically significant by the investigator. * 7\. Patients with known coagulation disorders such as bleeding tendency; or patients who need to use anticoagulants, which may affect the intramuscular injection of fulvestrant or the use of LHRH agonists. * 8\. Patients with known hypersensitivity or intolerance to all investigational drugs or their excipients, or any components of LHRH agonists (if applicable). * 9\. Patients with a history of autoimmune diseases (except tuberous sclerosis), a history of immunodeficiency diseases (including positive HIV test), or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
Conditions Breast Cancer
Phase PHASE3
Enrollment 450
Locations 242 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Inavolisib — Participants will receive oral inavolisib once daily (QD).
  • Drug: Placebo — Participants will receive oral placebo QD.
  • Drug: CDK4/6i — Participants will receive CDK4/6i on either Days 1-21 or Days 1-28 of each 28-day cycle.
  • Drug: Letrozole — Participants will receive oral letrozole QD.

Primary Outcomes

  • Progression-Free Survival (PFS) (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 7 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-04-09
Completion: 2032-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: WO45654 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Drug: Inavolisib — Participants will receive oral inavolisib once daily (QD).
  • Drug: Placebo — Participants will receive oral placebo QD.
  • Drug: CDK4/6i — Participants will receive CDK4/6i on either Days 1-21 or Days 1-28 of each 28-day cycle.
  • Drug: Letrozole — Participants will receive oral letrozole QD.
Study Locations (242 sites)
City of Hope - Phoenix, Goodyear, Arizona 85338 United States
The Dignity Health Cancer Institute, Phoenix, Arizona 85004 United States
Disney Family Cancer Center, Burbank, California 91505 United States
City of Hope - Lennar Foundation Cancer Center, Irvine, California 92618 United States
Scripps Health, La Jolla, California 92040 United States
City Of Hope, Long Beach, California 90813 United States
Cancer and Blood Specialty Clinic, Los Alamitos, California 90720 United States
Ellison Medical Institute, Los Angeles, California 90064 United States
Palo Alto Medical Foundation Research Center, Palo Alto, California 94301 United States
Kaiser Permanente - San Marcos, San Marcos, California 92069 United States
Eligibility Criteria
Inclusion Criteria: * Women or men with histologically or cytologically confirmed carcinoma of the breast * Documented ER-positive and/or progesterone receptor-positive tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Documented HER2-negative tumor according to ASCO/CAP guidelines * De-novo HR+ , HER2- ABC, or, alternatively, relapsed HR+ , HER2- ABC after at least 2 years of standard neoadjuvant/adjuvant endocrine therapy without disease progression during that treatment and disease-free interval of at least 1 year since the completion of that treatment * Participants who have bilateral breast cancers which are both HR-positive and HER2-negative * Confirmation of biomarker eligibility * Consent to provide fresh or archival tumor tissue specimen * Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Adequate hematologic and organ function within 14 days prior to initiation of study treatment Exclusion Criteria: * Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required * Metaplastic breast cancer * Any prior systemic therapy for locally advanced unresectable or metastatic breast cancer * Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes * Any history of leptomeningeal disease or carcinomatous meningitis * Known and untreated, or active CNS metastases. Participants with a history of treated CNS metastases are eligible * Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye * Symptomatic active lung disease * History of or active inflammatory bowel disease * Any active bowel inflammation * Prior hematopoietic stem cell or bone marrow transplantation * Treatment with strong cytochrome P450 (CYP) 3A4 inhibitors or strong CYP3A4 inducers within 4 weeks or 5 drug-elimination half-lives, prior to initiation of study treatment
Conditions Breast Cancer
Phase NA
Enrollment 225
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate and report the clinical adverse events and dosimetric parameters in breast cancer patients undergoing an "all-in-one (AIO)" one-stop, fully automated radiotherapy workflow. By systematically tracking these clinical and physical metrics, we seek to establish a standardized clinical protocol for AIO radiotherapy in breast cancer management.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Sequential Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Radiotherapy procedure — The workflow relies on specialized convolutional neural networks for automated segmentation and dose-prediction auto-planning. These breast cancer models were trained on 285 historical institutional cases spanning radical mastectomy and breast-conserving surgery over five years. Auto-delineated structures include the clinical target volume, regional lymph nodes (if involved), tumor bed (identified by surgical clips), heart, bilateral lungs, unaffected breast, spinal cord, esophagus, thyroid, and affected humeral head. These contours guide dose prediction to generate deliverable tangential arc plans via clinical-goal-guided automated optimization in the treatment planning system. To adapt to the on-couch treatment scenario, models were validated on retrospective data and offline routines to maximize target delineation accuracy and the first-approval rate of auto-plans.

Primary Outcomes

  • Acute adverse events (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-08-27
Completion: 2028-11-27
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 225 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Xiaoli Yu, MD, PhD
+86-021-64175590
xiaoliyu@fudan.edu.cn
Xiaofang Wang, MD, PhD
+86 18017317247
xiaofang0708@yeah.net
Xiaofang Wang Wang
+86 18017317247
xiaofang0708@yeah.net
Fudan University Shanghai Cancer Center
Interventions
  • Other: Radiotherapy procedure — The workflow relies on specialized convolutional neural networks for automated segmentation and dose-prediction auto-planning. These breast cancer models were trained on 285 historical institutional cases spanning radical mastectomy and breast-conserving surgery over five years. Auto-delineated structures include the clinical target volume, regional lymph nodes (if involved), tumor bed (identified by surgical clips), heart, bilateral lungs, unaffected breast, spinal cord, esophagus, thyroid, and affected humeral head. These contours guide dose prediction to generate deliverable tangential arc plans via clinical-goal-guided automated optimization in the treatment planning system. To adapt to the on-couch treatment scenario, models were validated on retrospective data and offline routines to maximize target delineation accuracy and the first-approval rate of auto-plans.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: * Histologically or pathologically confirmed breast cancer with definitive indications for radiotherapy (preoperative, postoperative, or radical) * ECOG performance status of 0-2 * Able to remain still and supine on the treatment couch for up to 30 minutes * Provision of signed, written informed consent * Able to comply with daily follow-ups and blood sample collections Exclusion Criteria: * Palliative radiotherapy for concurrent distant metastasis * Incomplete or ongoing chemotherapy * Synchronous multiple primary tumors * Current pregnancy or lactation * Prior history of radiotherapy to the ipsilateral breast, chest wall, thorax, or regional lymph nodes * Severe non-malignant comorbidities (e.g., cardiovascular or pulmonary diseases, systemic lupus erythematosus, scleroderma) resulting in a short life expectancy or inability to tolerate radical radiotherapy * Inability or unlikelihood to comply with study follow-up * Inability or unwillingness to provide written informed consent
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE1, PHASE2
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal donor TGFBi NK cells with or without naxitamab work for the treatment of patients with GD2 expressing, HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. TGFBi NK cells are manufactured cells that are a part of your natural immunity. NK cells can recognize missing or incorrect proteins on tumor cells and then eliminate these tumor cells and TGFBi NK cells are created to be able to better kill the tumor cells. Naxitamab is a monoclonal antibody that targets GD2, which is a protein or sugar present on tumor cells but not very commonly found on normal cells. This antibody helps draw the attention of the immune system to the tumor cells that have GD2 to help attack the tumor cells. Giving gemcitabine and TGFBi NK cells with or without naxitamab may kill more tumor cells in patients with metastatic GD2 expressing, HER2 negative breast cancer.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Computed Tomography — Undergo CT scan
  • Drug: Gemcitabine — Given IV
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Biological: Naxitamab — Given IV
  • Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells — Given IV

Primary Outcomes

  • Incidence of adverse events (Up to 1 year after completion of study medication)
  • Objective response rate (Up to 1 year after completion of study medication)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-04-02
Completion: 2027-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Margaret Gatti-Mays
Principal Investigators:
  • Margaret E Gatti-Mays, MD MPH (PRINCIPAL_INVESTIGATOR) - Ohio State University Comprehensive Cancer Center
Contact Information
Study Contact:
The Ohio State University Comprehensive Cancer Center
800-293-5066
OSUCCCClinicaltrials@osumc.edu
Amanda Kabetso
614-257-2400
amanda.kabetso@osumc.edu
Margaret E. Gatti-Mays, MD, MPH
614-293-0066
Ohio State University Comprehensive Cancer Center
Interventions
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Computed Tomography — Undergo CT scan
  • Drug: Gemcitabine — Given IV
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Biological: Naxitamab — Given IV
Study Locations (1 sites)
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Patients must have histologically or cytologically confirmed, HER2 negative metastatic breast cancer that is historically GD2 expressing (e.g., triple negative breast cancer, metaplastic breast cancer, high grade 3 estrogen positive breast cancer at initial diagnosis) with available archival tissue. Well differentiated neuroendocrine tumor (NETs) are not eligible for this trial since GD2 expression is unknown. GD2 expression is not required for eligibility but a primary tumor paraffin block is required at enrollment for assessment of GD2 expression * Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for the evaluation of measurable disease * Patients must have received at least one prior treatment for metastatic disease and progressed on treatment or been intolerant to treatment * Female or male \>=18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Absolute neutrophil count \>= 1,500/mcL (\> 1.5 X 10\^6/L) * Platelets \>= 100,000/mcL * Hemoglobin \>= 9 mg/dL (transfusion to obtain hemoglobin \>= 9 mg/dL within 24 hours prior to dosing is allowed) * Serum creatinine =\< 1.5 X upper limit of normal (ULN) or measured or calculated creatinine clearance (CrCl) \>= 60 mL/min for participant with creatinine levels \> 1.5 X institutional upper limit of normal (ULN) (Glomerular filtration rate \[GFR\] can also be used in place of creatinine or CrCl) * Patients must have adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =\< 3 X ULN and total bilirubin \< 1.5 X ULN, unless known diagnosis of Gilbert's syndrome, where bilirubin =\< 5 mg/dL will be permitted. Gilbert's syndrome will be defined as elevated unconjugated bilirubin, with conjugated (direct) bilirubin within the normal range and less than 20% of the total. Total bilirubin will be permitted up to 5 mg/dL, if patients have historical readings consistent with the definition of Gilbert's syndrome prior to entering study. Adequate hepatic function for patients with known liver metastases is defined as AST and ALT levels ≤ 5 X ULN * The effects of the trial agents on the developing human fetus are unknown. However, gemcitabine is known to have negative fetal effects. For this reason: Women of childbearing potential must agree to use adequate contraception at study entry, for the duration of study participation and for 7 months after the last dose of study medication based upon estimated half-life or receptor occupancy. Adequate contraception is defined as 2 highly effective methods of contraception (including a physical barrier). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men should refrain from fathering a child using adequate contraception or donating sperm during the study and for 6 months after the last dose of study medications. Adequate contraception is defined as 2 highly effective methods of contraception (including a physical barrier) * Patients with well-controlled human immunodeficiency virus (HIV) infection are eligible for trial as long as: * On an effective anti-retroviral therapy (ART) ˃ 4 weeks and with evidence of viral-suppression as defined as HIV viral load ˂ 400 copies/mL within the last 3 months * CD4 \> 200 cells/µL within the last 3 months; and * No reported opportunistic infections within 6 months prior to enrollment, except for the following which will be allowed: * Esophageal candidiasis treated within last 6 months or currently improving with antifungal treatment. * Oral and/or genital herpes simplex virus (HSV) treated within last 6 months or currently improving with antiviral treatment. * Mycobacterium avium infection in last 6 months or that has been treated for at least 1 month * Patients with evidence of chronic hepatitis B virus (HBV) infection are eligible for trial as long as the HBV viral load is undetectable on suppressive therapy, if indicated. * Patients with history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable or unquantifiable HCV ribonucleic acid (RNA) 12 weeks or longer after definitive treatment completion. * Patients must be able to understand and willing to sign a written informed consent document * Any adverse events subjects have experienced from prior therapy must have resolved to =\< grade 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 Exclusion Criteria: * Patients who within 3 weeks prior to study enrollment who have received chemotherapy, investigational agents, or radiation * Patients with active brain metastases or leptomeningeal metastases are excluded from this clinical trial because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. However, patients with treated brain metastases are eligible if there is no magnetic resonance imaging (MRI) evidence of progression for 6 months after treatment is complete and within 28 days prior to the first dose of trial drug. Patients requiring immunosuppressive doses of systemic corticosteroids (\> 10mg/day prednisone equivalent) for palliation are excluded * Patients with a history of another invasive malignancy \< 3 years prior to enrollment (patients with non-melanoma skin cancers, carcinoma in situ of the breast or cervix are eligible) * History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study * Uncontrolled intercurrent illness including, but not limited to, ongoing active infection that requires systemic treatment with ongoing antibiotics (eligible if can stop antibiotics on day of enrollment), unexplained fever (temperature \> 38.1˚celcius \[C\]) within 7 days of initial treatment, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that in the opinion of the primary investigator would prohibit the patient from complying with study requirements * Patients with bone metastases who have initiated denosumab or a bisphosphonate therapy within 28 days prior to or after cycle 1 day 1 due to the potential for flu-like symptoms and mild cytokine release syndrome with the initial dose. However, continuation of prior therapy is allowed * Patients should have no evidence of being immunocompromised as listed below: * Active, known or suspected autoimmune disease. Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger in the opinion of the primary investigator * Altered immune function that in the judgement of the PI that may affect a patient's ability to adequately engage the immune system and respond to the immunotherapy agents being administered, including but not limited to: inflammatory bowel disease; active infectious enteritis; eosinophilic enteritis; lupus erythematous; ankylosing spondylitis; scleroderma; multiple sclerosis. These criteria do not include all disease with an immune-related component but are not autoimmune in nature or have a primary alteration in the general immune function that may interfere with the vaccine mechanism of action, for example celiac disease * Immunosuppressive therapy post-organ transplant * Concurrent use of chronic use of systemic steroids, except for physiologic doses of systemic steroids for replacement, defined as 10mg of prednisone per day or equivalent, or local (topical, nasal, ophthalmic or inhaled) steroid use or prior concomitant use with chemo
Conditions Triple-Negative Breast Cancer (TNBC), Br...
Phase PHASE2
Enrollment 39
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab govitecan) treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or the investigator deems it necessary to discontinue the medication, and to collect data on the drug's efficacy and safety.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ivonescimab Combined With TROP2 ADC — Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;

Primary Outcomes

  • Intracranial objective response rate (CNS ORR) (Up to approximately 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-17
Completion: 2027-01-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 39 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Jian Zhang, MD,PhD
+8618017312991
syner2000@163.com
Yiqun Du, MD, PhD
+8618121299359
dyqlh2010@163.com
Fudan University Shanghai Cancer center
Interventions
  • Drug: Ivonescimab Combined With TROP2 ADC — Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;
Study Locations (1 sites)
Fudan University Shanghai Cancer center, Shanghai, Shanghai Municipality China 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years and ≤ 70 years, with no gender restrictions; 2. ECOG performance score of 0 to 2; 3. Expected survival ≥ 3 months; 4. Patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed treatment with taxane drugs are included. 5. Ten tissue pathology slides of the primary lesion and/or metastatic lesion (preferably metastatic lesion) can be obtained before the start of treatment for exploratory analysis of molecular indicators related to therapeutic efficacy. 6. Patients must have brain metastases confirmed by MRI, with at least one brain metastasis lesion that previously has not received radiotherapy and has a longest diameter of ≥ 1.0 cm; for brain metastasis lesions that have received local treatment, progression must be confirmed by imaging examination; 7. Cohort A: Patients with brain metastases who have not received central nervous system radiotherapy before. Patients with new brain lesions after craniotomy are allowed to be included, provided that they have not received radiotherapy after surgery and at least 2 weeks have passed since the surgery; 8. Cohort B: Patients with lesion progression or new lesions after whole brain radiotherapy (WBRT) or stereotactic radiotherapy (SRT). If a patient has multiple central nervous system lesions and only one or a few of them have received SRT treatment, and there are untreated lesions, such patients are still eligible for inclusion in this study; 9. The use of mannitol or hormones for treatment is allowed before enrollment, but the hormone treatment dose should be stable for at least one week without the need for an increase; 10. All patients enrolled are required to have adequate hematologic, hepatic, and renal function; 11. Be able to understand the study procedures and sign informed consent. Exclusion Criteria: 1. Patients with soft meningeal metastases confirmed by MRI or lumbar puncture; 2. Presence of third-space effusion that cannot be controlled by drainage or other methods (such as large amounts of pleural effusion and ascites); 3. Received whole brain radiotherapy, chemotherapy, or surgery within 2 weeks before the treatment with the investigational drug, or received targeted therapy or endocrine therapy within 1 week before the treatment; 4. Previously used monoclonal or bispecific antibodies containing anti-VEGF-A and anti-PD-1/PD-L1/CTLA-4; previously used TROP2 ADC drugs. 5. Participated in other drug clinical trials within 2 weeks before enrollment; 6. Simultaneously receiving any anti-tumor treatment for other tumors; 7. Had other malignant tumors within the past 5 years, excluding cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin, differentiated thyroid cancer, etc. that have been cured; 8. Patients with severe heart diseases, including: (1) Congestive heart failure (NYHA class \> 2); (2) History of unstable angina pectoris; (3) Myocardial infarction within the past 48 weeks; (4) Clinically significant arrhythmias (excluding atrial fibrillation and paroxysmal supraventricular tachycardia); (5) Any other heart diseases deemed by the investigator as unsuitable for participation in this trial; 9. Known hypersensitivity to the components of the investigational drug; 10. Uncontrolled serious infection. 10\. History of immunodeficiency, including HIV positive, active hepatitis C virus infection or other acquired or congenital immunodeficiency diseases, or history of organ transplantation; patients with positive hepatitis B surface antigen (HBsAg) and HBV DNA \> 2000 IU/ml or \> 104 copies/ml should receive antiviral treatment according to local treatment guidelines and be willing to receive antiviral treatment throughout the study period; 11. Use of live attenuated vaccines within 28 days before randomization, or expected to use such vaccines during the study period (patients are not allowed to receive live attenuated influenza vaccine within 4 weeks before randomization, during treatment, and within 5 months after the last dose of SHR-1316/placebo); 12. Active, known or suspected autoimmune diseases, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc. Type 1 diabetes (controlled by insulin), hypothyroidism due to autoimmune thyroiditis that only requires hormone replacement therapy, or conditions that are not expected to recur without external stimulation are allowed. Patients with eczema, psoriasis, chronic simple lichen or only with skin manifestations of vitiligo (excluding psoriatic arthritis) can be enrolled if the rash covers less than 10% of the body surface area, the disease is well controlled at baseline and only requires low-potency topical steroids, and there has been no acute exacerbation of the underlying disease in the past 12 months (no need for psoralen plus ultraviolet radiation \[PUVA\], methotrexate, retinoids, biologics, oral calcineurin inhibitors, high-potency or oral steroids); 13. History of definite neurological or mental disorders, including epilepsy or dementia; 14. Pregnant or lactating women, women of childbearing age with positive baseline pregnancy test, or women who are unwilling to take effective contraceptive measures throughout the study period; 15. According to the investigator's judgment, patients with severe concomitant diseases that may endanger their safety or affect their completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection, thyroid disease, etc.); 16. Any other conditions deemed by the investigator as unsuitable for participation in this study.